Amgen Inc. said it plans to periodically sell up to $200 million of debt securities, with terms to be determined by market conditions.
The Thousand Oaks-based biotechnology concern said it would use the proceeds for general corporate purposes.
Amgen has become the nation's leading biotechnology company on the strength of its first two marketable drugs, and has relatively little long-term debt--$12 million. The additional debt securities sales would, among other things, help Amgen finance its research and development of new products.
